Roche

Belkins
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

INDUSTRIAL IMPACT

LARONDE ATTRACTS $440M IN FIRST EXTERNAL FINANCING TO FURTHER ADVANCE ENDLESS RNA™ PLATFORM

Laronde | August 30, 2021

news image

Laronde, the company pioneering Endless RNA™ a novel, engineered form of RNA that can be programmed to express therapeutic proteins inside the body, today announced that it has raised $440 Million in a Series B Financing to advance the development of its eRNA platform and a broad pipeline of programs across a number of therapeutic categories. The financing round included the company's founder, Flagship Pioneering, along with funds and accounts advised by T. Rowe Price Associates, Inc.,...

Read More

ECOGEN LABORATORIES ANNOUNCES OPERATIONAL UPDATE AMID COVID-19 PANDEMIC

BioSpace | March 20, 2020

news image

EcoGen Laboratories ("EcoGen"), the leading vertically-integrated manufacturer and supplier of high quality hemp genetics, hemp-derived specialty ingredients and finished products in North America, released the following statement today from the Company's Co-Founder and CEO Alexis Korybut regarding operational updates amid the COVID-19 pandemic....

Read More

BOLDER BIOTECHNOLOGY ANNOUNCES POSITIVE PRECLINICAL DATA FOR USE OF BBT-032 TO INHIBIT GROWTH OF THE SARS-COV-2 VIRUS

PR Newswire | August 26, 2020

news image

Bolder BioTechnology, Inc. announced today that preclinical studies have shown that its proprietary long-acting interferon beta analog, BBT-032, strongly inhibits growth of the SARS-CoV-2 virus in culture at concentrations expected to be readily achievable in patients. SARS-CoV-2 is the coronavirus responsible for the Covid-19 pandemic.Based upon these promising results, Bolder BioTechnology intends to file an Investigational New Drug Application with the U.S. Food and Drug Administration ...

Read More

AI

LABCORP AND PATHAI EXPAND THEIR PARTNERSHIP TO ACCELERATE USE OF AI-POWERED PATHOLOGY

PathAI, Labcorp | March 09, 2021

news image

PathAI, a global supplier of artificial intelligence-powered (AI-powered) innovation for use in pathology research, and Labcorp, a main global life sciences company, today declared the expanding of their essential organization in the field of AI-powered pathology. The coordinated effort expands on Labcorp's past investment in PathAI and the companies' cooperation on a progression of projects, remembering the deployment of PathAI algorithms for clinical trials oversaw by Labcorp Drug Deve...

Read More

INDUSTRIAL IMPACT

Laronde | August 30, 2021

news image

LARONDE ATTRACTS $440M IN FIRST EXTERNAL FINANCING TO FURTHER ADVANCE ENDLESS RNA™ PLATFORM

Laronde, the company pioneering Endless RNA™ a novel, engineered form of RNA that can be programmed to express therapeutic proteins inside the body, today announced that it has raised $440 Million in a Series B Financing to advance the development of its eRNA platform and a broad pipeline of programs across a number of therapeutic categories. The financing round included the company's founder, Flagship Pioneering, along with funds and accounts advised by T. Rowe Price Associates, Inc.,...

Read More

BioSpace | March 20, 2020

news image

ECOGEN LABORATORIES ANNOUNCES OPERATIONAL UPDATE AMID COVID-19 PANDEMIC

EcoGen Laboratories ("EcoGen"), the leading vertically-integrated manufacturer and supplier of high quality hemp genetics, hemp-derived specialty ingredients and finished products in North America, released the following statement today from the Company's Co-Founder and CEO Alexis Korybut regarding operational updates amid the COVID-19 pandemic....

Read More

PR Newswire | August 26, 2020

news image

BOLDER BIOTECHNOLOGY ANNOUNCES POSITIVE PRECLINICAL DATA FOR USE OF BBT-032 TO INHIBIT GROWTH OF THE SARS-COV-2 VIRUS

Bolder BioTechnology, Inc. announced today that preclinical studies have shown that its proprietary long-acting interferon beta analog, BBT-032, strongly inhibits growth of the SARS-CoV-2 virus in culture at concentrations expected to be readily achievable in patients. SARS-CoV-2 is the coronavirus responsible for the Covid-19 pandemic.Based upon these promising results, Bolder BioTechnology intends to file an Investigational New Drug Application with the U.S. Food and Drug Administration ...

Read More

AI

PathAI, Labcorp | March 09, 2021

news image

LABCORP AND PATHAI EXPAND THEIR PARTNERSHIP TO ACCELERATE USE OF AI-POWERED PATHOLOGY

PathAI, a global supplier of artificial intelligence-powered (AI-powered) innovation for use in pathology research, and Labcorp, a main global life sciences company, today declared the expanding of their essential organization in the field of AI-powered pathology. The coordinated effort expands on Labcorp's past investment in PathAI and the companies' cooperation on a progression of projects, remembering the deployment of PathAI algorithms for clinical trials oversaw by Labcorp Drug Deve...

Read More